Blood DNA methylation and breast cancer risk: A meta-analysis of four prospective cohort studies

C Bodelon; S Ambatipudi; PA Dugué; A Johansson; JN Sampson; B Hicks; E Karlins; A Hutchinson; C Cuenin; V Chajès; MC Southey; I Romieu; GG Giles; D English; S Polidoro; M Assumma; L Baglietto; P Vineis; G Severi; Z Herceg; JM Flanagan; RL Milne; M Garcia-Closas

Journal article

Blood DNA methylation and breast cancer risk: A meta-analysis of four prospective cohort studies

C Bodelon, S Ambatipudi, PA Dugué, A Johansson, JN Sampson, B Hicks, E Karlins, A Hutchinson, C Cuenin, V Chajès, MC Southey, I Romieu, GG Giles, D English, S Polidoro, M Assumma, L Baglietto, P Vineis, G Severi, Z Herceg Show all

Breast Cancer Research | BMC | Published : 2019

DOI: 10.1186/s13058-019-1145-9

Download PDF

Abstract

Background: Environmental and genetic factors play an important role in the etiology of breast cancer. Several small blood-based DNA methylation studies have reported risk associations with methylation at individual CpGs and average methylation levels; however, these findings require validation in larger prospective cohort studies. To investigate the role of blood DNA methylation on breast cancer risk, we conducted a meta-analysis of four prospective cohort studies, including a total of 1663 incident cases and 1885 controls, the largest study of blood DNA methylation and breast cancer risk to date. Methods: We assessed associations with methylation at 365,145 CpGs present in the HumanMethyla..

View full abstract

University of Melbourne Researchers

Melissa Southey Author

Graham Giles Author

Dallas English Author

Roger Milne Author

Grants

Awarded by Fondation ARC pour la Recherche sur le Cancer

Funding Acknowledgements

This research was partially supported by the Intramural Research Program of the National Institutes of Health, National Cancer Institute, Division of Cancer Epidemiology and Genetics. The work performed by the Epigenetics Group at IARC was supported by grants from the Institut National du Cancer (INCa, France), the European Commission (EC) Seventh Framework Programme (FP7) Translational Cancer Research (TRANSCAN) Framework, the Fondation ARC pour la Recherche sur le Cancer (France), and la Ligue Nationale (Francaise) Contre le Cancer to ZH. The MCCS methylation work was supported by the National Health and Medical Research Council (grant number 1011618) and the Victorian Breast Cancer Research Consortium. The work performed at Imperial College London was funded by the Breast Cancer Now and supported by the Cancer Research UK Imperial Centre.